David Amsellem


Why This Analyst is Putting Valeant Pharmaceuticals Intl Inc (VRX) on the Back Burner

Piper Jaffray reiterated Underperform on VRX stock; Sees 25% downside for the stock

Analysts Disagree Over Significance of Akorn, Inc.’s Financial Errors (AKRX)

Akorn, Inc. (NASDAQ:AKRX) announced on Friday that it will have to restate financials from 2014 due to accounting errors.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts